GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.

As of 10/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  12/23/2020
Outstanding shares:  14,882,522
Average volume:  330,697
Market cap:   $30,509,170
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    36151G105
ISIN:        US36151G1058
Valuation   (See tab for details)
PE ratio:   -5.24
PB ratio:   1.90
PS ratio:   841.15
Return on equity:   -46.87%
Net income %:   -19,389.95%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy